L&G Pharma Breakthrough UCITS ETF ISIN IE00BF0H7608, WKN A2H9XR

 
Add to portfolio Watch Compare
 
 
 
 

Current quote and strategy of L&G Pharma Breakthrough UCITS ETF

Quote
EUR 10.49
Last quote
26.05.23
9.50 52 weeks low/high 11.34
52 weeks low/high
Savings plan ready
Show all offers
 
Investment strategy

The L&G Pharma Breakthrough UCITS ETF seeks to track the Solactive Pharma Breakthrough Value index. The Solactive Pharma Breakthrough Value index tracks companies involved in the development and manufacturing of so-called "orphan drugs". Orphan drugs are drugs that target very rare diseases.

 

Solactive Pharma Breakthrough Value (1)

Equity (1581) World (461) Health Care (23) Innovation (13)
 
Beta Try our new version of the ETF Profile now!   Try now!  

Risk and fees of L&G Pharma Breakthrough UCITS ETF

Risk
EUR 57 m
Fund size
Fund size category

Replication

Physical (Full replication)
Legal structure ETF
Strategy risk Long-only
Fund currency USD

Currency risk

Currency unhedged
Volatility 1 year (in EUR) 18.84% Risk category
Inception/ Listing Date 23 January 2018
Fees
0.49% p.a.
Total expense ratio
0.04% Compare 1.38%
Compare ( Equity )
Dividend/ Taxes
Distribution policy Accumulating
Distribution frequency -
Fund domicile Ireland
Tax data Bundesanzeiger
Legal structure
Fund Structure Open-ended Investment Company (OEIC)
UCITS compliance Yes
Fund Provider Legal & General (LGIM)
Administrator BNY Mellon Fund Services (Ireland) Limited
Investment Advisor Legal & General Investment Management Limited
Custodian Bank BNY Mellon Trust Company (Ireland) Limited
Revision Company EY
Fiscal Year End 30 June
Swiss representative State Street Bank International GmbH, München, Zweigniederlassung Zürich
Swiss paying agent State Street Bank International GmbH, München, Zweigniederlassung Zürich
Tax Status
Germany 30% tax rebate
Switzerland No ESTV Reporting
Austria Tax Reporting Fund
UK UK Reporting
Replication, swap, securities lending
Indextype Total return index
Swap counterparty -
Collateral manager BNY Mellon Fund Services (Ireland) Limited
Securities lending No
Securities lending counterparty
 
 
 

Performance of L&G Pharma Breakthrough UCITS ETF

Loading...
 
 

Savings plan offers for the L&G Pharma Breakthrough UCITS ETF

Select your savings amount:

 
Broker Rating Savings plan offer Brokerage fee More information
free of charge
free of charge
More info
free of charge
free of charge
More info
free of charge
free of charge
More info
EUR 1.50
1.50%
free of charge
More info
EUR 1.50
1.50%
free of charge
More info
Show all offers
 
 

Exposure

Below you find information about the composition of the L&G Pharma Breakthrough UCITS ETF.

Countries
United States
49.48%
Japan
16.41%
Ireland
6.39%
China
5.84%
Other
21.88%
Show more
Sectors
Health Care
99.83%
As of 30/03/2023
 
 

Description of L&G Pharma Breakthrough UCITS ETF

The L&G Pharma Breakthrough UCITS ETF invests in stocks with focus Innovation, Health Care, World. The dividends in the fund are reinvested (accumulating).

The total expense ratio amounts to 0.49% p.a.. The fund replicates the performance of the underlying index by buying all the index constituents (full replication). The L&G Pharma Breakthrough UCITS ETF is a small ETF with 57m Euro assets under management. The ETF is older than 5 years and is domiciled in Ireland.
 

Look for similar ETFs

 
 

Returns of L&G Pharma Breakthrough UCITS ETF

Returns in years
Loading...
Returns in periods
Loading...
 
Monthly returns in a heat map
Loading...
 
 

Listings of L&G Pharma Breakthrough UCITS ETF

Loading...
 

Rolling 1 year volatility of L&G Pharma Breakthrough UCITS ETF

Loading...
 
Volatility 1 year Volatility 3 years Volatility 5 years
18.84% 17.66% 20.09%
Return per risk 1 years Return per risk 3 years Return per risk 5 years
0.19 -0.03 0.23
 

Frequently asked questions

What is the name of ETLI?

The name of ETLI is L&G Pharma Breakthrough UCITS ETF.

What is the ticker of L&G Pharma Breakthrough UCITS ETF?

The primary ticker of L&G Pharma Breakthrough UCITS ETF is ETLI.

What is the ISIN of L&G Pharma Breakthrough UCITS ETF?

The ISIN of L&G Pharma Breakthrough UCITS ETF is IE00BF0H7608.

What are the costs of L&G Pharma Breakthrough UCITS ETF?

The total expense ratio (TER) of L&G Pharma Breakthrough UCITS ETF amounts to 0.49% p.a.. These costs are withdrawn continuously from the fund assets and already included in the performance of the ETF. You don't have to pay them separately. Please have a look at our article for more information about the cost of ETFs.

Is L&G Pharma Breakthrough UCITS ETF paying dividends?

L&G Pharma Breakthrough UCITS ETF is an accumulating ETF. This means that dividends are not distributed to investors. Instead, dividends are reinvested in the fund on the ex-date, which leads to an increase of the ETF's share price.

What's the fund size of L&G Pharma Breakthrough UCITS ETF?

The fund size of L&G Pharma Breakthrough UCITS ETF is 57m Euro. See the following article for more information about the size of ETFs.

Track your ETF strategies online

 
— Data provided by Trackinsight, etfinfo, Xignite Inc. and justETF GmbH.

All quotes are 15 minutes delayed stock exchange quotes or NAVs (=daily published by fund provider). Returns include dividend payments. There is no warranty for completeness, accuracy and correctness for the displayed information.